As a major profibrotic factor in fibrotic disorders, anti-TGF-β treatment prevented skin and lung fibrosis in a mouse model for scleroderma (40); administration of TGF-β1-directed antibody prevented ECM matrix protein expression from injured vascular smooth muscle cell lines (41). The gene discussed is TGFB1; the disease is scleroderma.